Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Issue 4 (October 2021)

• Record Type: Journal Article
• Authors: Redenbaugh, Vyanka; Montalvo, Mayra; Sechi, Elia; Buciuc, Marina; Fryer, James P.; McKeon, Andrew; Lennon, Vanda A.; Mills, John R.; Weinshenker, Brian G.; Wingerchuk, Dean M.; Chen, John J.; Tariq Bhatti, M.; Lopez Chiriboga, A. Sebastian; Pittock, Sean J.; Flanagan, Eoin P.
• Is Part Of: Multiple sclerosis journal, experimental, translational and clinical. Volume 7:Issue 4(2021)
• Publication Date: 2021-10
• Subjects: Multiple sclerosis -- Periodicals; 616.834
• DOI: 10.1177/20552173211052656
• Languages: English
• ISSNs: 2055-2173

Abstract

Objective: Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods: We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results: Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions: AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.